Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

thestreet.com — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag is abbreviated and delivered a day early due to the Fourth of July. Happy hot dogs and fireworks, everyone! @adamfeuerstein Let's get a halftime update!

MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

thestreet.com — BOSTON ( TheStreet) -- The number of prescriptions written for MannKind's inhaled insulin Afrezza are barely making a dent in the diabetes market five months since partner Sanofi launched the product. Afrezza is even under-performing Exubera, the first inhaled insulin launched by Pfizer in 2006.

Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

thestreet.com — SUMMIT, NJ ( TheStreet) -- Celgene was known as the savviest collaborative deal maker in biotech. That honorific has to be called into question after Celgene announced a plan Monday to buy a $1 billion, stake in Juno Therapeutics and its CAR-T cancer immunotherapy platform at more than twice Juno's current market value.

Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

thestreet.com — BOSTON ( TheStreet) -- Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients. Sales of the new Vertex cystic fibrosis drug, Orkambi, are also expected to transform Vertex into a sustainably profitable company for the first time since its founding in 1989.

Sarepta Submits DMD Drug for FDA Approval Review

thestreet.com — CAMBRIDGE, Mass. ( TheStreet) -- Sarepta Therapeutics completed the submission of a new drug application to U.S. regulators seeking the approval of eteplirsen for the treatment of patients with Duchenne muscular dystrophy (DMD), the company announced Monday. Getting eteplirsen filed with the U.S.

Biotech Stock Mailbag: Exelixis (EXEL), Puma Bio (PBYI)

thestreet.com — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag examines the next stock-moving catalysts for Exelixis and Puma Biotechnology . No hate mail this week, sorry. @adamfeuerstein Hi Adam, any thought at all on $EXEL - jdubbs (@jweil130) June 23, 2015 In July, Exelixis is expected to announce results from the "METEOR" phase III study of Cometriq in second-line kidney cancer.

Alcobra Placebo Beats Drug in Failed Genetic Disease Study

thestreet.com — TEL AVIV, Israel ( TheStreet) -- Count with me the ways in which Alcobra's experimental drug MDX failed to benefit patients with Fragile X syndrome, a genetic disease which causes intellectual and behavioral disabilities: MDX missed the primary endpoint of the phase II study. In fact, placebo patients performed better, Alcobra admitted.

Agenus (AGEN) Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist

thestreet.com — BOSTON ( TheStreet) -- We've reached the stage of the biotech bull market where a sell-side analyst can value a company on sales of a cancer drug that doesn't exist. I'm referring to Christopher Marai, biotech analyst at Oppenheimer & Co.

Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!

thestreet.com — BOSTON ( TheStreet) -- The big move by Heron Therapeutics since the end of May generated a ton of reader email and tweets for this week's Biotech Stock Mailbag. Most of the comments I've received are skeptical, questioning Heron's suddenly upsized market value relative to the future commercial potential of its lead drug Sustol, which aims to reduce nausea and vomiting in cancer patients undergoing chemotherapy.

Receptos (RCPT) Analyst Defends Company but Sounds Confused

thestreet.com — BOSTON ( TheStreet) -- I have some beefs with Leerink Partners biotech analyst Joe Schwartz and his research note published Wednesday night in which he attempted to rebut my story about Receptos and why an insider stock sale makes an imminent takeout unlikely.
More Articles →
Jul 02, 2015

RT @VertexPharma: Tech issue w/ our website. See investor webcast here: bit.ly/1e6ECxb or dial in w/info from our press release bit.ly/1isUsLc

Jul 02, 2015

@mcgowankat Ask a CF patient what fewer lung exacerbations and trips to hospital are worth.

Jul 02, 2015

@VikramKhanna_ In Foster City, someone is saying, “Hi $VRTX, your turn to be the whipping boy…”

Jul 02, 2015

@VikramKhanna_ I’d say pushback on Orkambi price, whatever it is, almost guaranteed.

Jul 02, 2015

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point thestreet.com/story/13207196… Can you tell I want wknd to start?

Email Adam by joining Muck Rack



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile